QNCX updates ATM: 4.82M shares sold, $6.5M gross to date

Rhea-AI Filing Summary

Quince Therapeutics (QNCX) filed a prospectus supplement for an at‑the‑market offering of up to $75,000,000 of common stock under its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC.

As of this supplement, the company has sold 4,823,859 shares for $6,496,274 in gross proceeds, leaving $68,503,726 available for future sales under the program. The company states it is currently no longer subject to the offering limits of General Instruction I.B.6. of Form S-3; if it becomes subject again, it will file another supplement.

QNCX common stock trades on Nasdaq under “QNCX.” The closing price was $1.93 on October 16, 2025.

Insights

Capital markets analyst

Administrative ATM update: $75M authorized; $68.5M capacity remains.

Quince Therapeutics maintains an active at‑the‑market (ATM) program for up to $75,000,000 of common stock under a Sales Agreement with Cantor Fitzgerald and H.C. Wainwright. ATMs allow issuers to sell shares into the market over time at prevailing prices.

The company reports cumulative sales of 4,823,859 shares for gross proceeds of $6,496,274, leaving $68,503,726 available. The supplement notes the company is currently not limited by General Instruction I.B.6., which had previously capped issuance relative to public float.

Future activity depends on market conditions and company decisions; the filing lists current capacity and counterparties. The last reported price was $1.93 on October 16, 2025.

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-283897

Prospectus Supplement

(to Prospectus dated December 26, 2024 and

the Prospectus Supplement dated March 24, 2025)

Up to $75,000,000

Common Stock

This prospectus supplement amends and supplements the information in the prospectus, dated December 26, 2024, filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-283897), as supplemented by the prospectus supplement dated March 24, 2025 (as supplemented, the Prior Prospectus), relating to the offer and sale of up to $75,000,000 of shares of our common stock, $0.001 par value per share, pursuant to the Controlled Equity Offering^SM Sales Agreement dated as of December 18, 2024, or the Sales Agreement, we previously entered into with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC, or the Agents. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus and any future amendments or supplements thereto.

The prospectus supplement dated March 24, 2025, indicated that we were, at that time, subject to General Instruction I.B.6. of Form S-3, which limited the amount that we were able to sell under the registration statement of which the prospectus forms a part. We are currently no longer subject to the offering limits imposed by General Instruction I.B.6. of Form S-3. If we become subject to the offering limits in General Instruction I.B.6. of Form S-3 in the future, we will file another prospectus supplement.

As of the date of this prospectus supplement, we have sold an aggregate of 4,823,859 shares for gross proceeds of $6,496,274 pursuant to the Sales Agreement. As a result of such prior sales, as of the date of this prospectus supplement, shares having an aggregate offering price of up to $68,503,726 remain available for offer and sale under the Sales Agreement through the Prospectus.

Our common stock is listed on the Nasdaq Global Select Market under the symbol “QNCX.” On October 16, 2025, the closing sale price of our common stock on the Nasdaq Global Select Market was $1.93 per share.

Investing in our common stock involves a high degree of risk. Please read the information contained in and incorporated by reference under the heading “Risk Factors” beginning on page 3 of the Prior Prospectus, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement and the Prior Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement and the Prior Prospectus. Any representation to the contrary is a criminal offense.

Cantor H.C. Wainwright & Co.

The date of this prospectus supplement is October 17, 2025

FAQ

What is Quince Therapeutics (QNCX) offering in this prospectus supplement?

An at‑the‑market offering of up to $75,000,000 of common stock under its Sales Agreement.

How much ATM capacity remains available for QNCX?

$68,503,726 remains available for offer and sale under the Sales Agreement.

How much has QNCX sold to date under the ATM and for what proceeds?

It has sold 4,823,859 shares for $6,496,274 in gross proceeds.

Who are the agents for Quince Therapeutics’ ATM program?

Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC.

Is QNCX currently subject to General Instruction I.B.6. limits?

The company states it is currently no longer subject to I.B.6. offering limits.

What was QNCX’s last closing price mentioned?

The closing price was $1.93 on October 16, 2025.